Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP

Sponsor
Medical University of Vienna
Study ID
NCT06398873
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps
  • Chronic Rhinosinusitis Without Nasal Polyps

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The investigators aim to investigate two major so far unresolved topics in CRSwNP research: (1) Thorough functional and molecular characterisation of barrier function in patients suffering from CRSsNP and CRSwNP and (2) effect of dupilumab treatment on barrier function in polyp patients. This will be achieved in patient-derived samples by employing measurement of barrier function in primary cell cultures in combination with a mass cytometry based imaging approach, transcriptomic analysis as well as cytokine and microbiome data of individual patients.

Key Dates

Start date
Jun 6, 2024
Status verified
Jun 2024
Primary completion
Sep 1, 2026
Completion
Sep 1, 2027

Study Design

Enrollment
80 participants (estimated)

Arms

  • Arm: CRSsNP
  • Arm: CRSwNP
    Dupilumab

Primary Outcome Measure

Barrier function in CRSsNP and CRSwNP [ Time Frame: 1 Visit (baseline) ]

Related Studies